Taiwanese startup Deep01 has signed exclusive agents for its AI-based ICH detection system DeepCT in more than 20 countries already.
Deep01, a Taiwanese startup that focuses on applying AI on medical imaging, has been having impressive developments recently. The company has signed exclusive agents for its AI-based intracranial hemorrhage (ICH) detection system—DeepCT—in more than 20 countries already across Asia, the Middle East, and Africa, including Japan, Malaysia, Thailand, Indonesia, the Philippines, and Vietnam.
Deep01’s DeepCT aims to help clinicians make better and faster decisions. After joining BE Health Ventures’ POC program in Taiwan Tech Arena, clinical validation outcomes of DeepCT has proven it efficacy and efficiency in hospital routine works. The system is already applied in more than 10 hospitals in Taiwan, including regional hospitals and medical centers, and more than 20,000 cases have already benefited from Deep01’s AI system.
With US, Taiwan FDA, and CE approvals, Deep01 is actively entering the global market and is particularly keen on developing partners in Europe.
“Our next step is getting certificates in each contracted region before starting to sell,” said David Chou, founder and CEO of Deep01. “We expect to deliver 1,000 or more sets of our AI system in the coming three years. We hope to bring AI healthcare to every corner in the world. Everyone can benefit from this innovative technology.”
Stephen Las Marias is the editor of EETimes Asia. He may be reached at email@example.com.